Protara Therapeutics Company Insiders

TARA Stock  USD 5.12  0.02  0.39%   
Protara Therapeutics employs about 28 people. The company is managed by 12 executives with a total tenure of roughly 66 years, averaging almost 5.0 years of service per executive, having 2.33 employees per reported executive. Analysis of Protara Therapeutics' management performance can provide insight into the company performance.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.

Protara Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Protara Therapeutics' future performance. Based on our forecasts, it is anticipated that Protara will maintain a workforce of about 30 employees by November 2025.
 
Yuan Drop
 
Covid

Protara Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2772) % which means that it has lost $0.2772 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4302) %, meaning that it created substantial loss on money invested by shareholders. Protara Therapeutics' management efficiency ratios could be used to measure how well Protara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of October 28, 2025, Return On Tangible Assets is expected to decline to -0.26. In addition to that, Return On Capital Employed is expected to decline to -0.3. At present, Protara Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 13.8 M, whereas Other Assets are forecasted to decline to 1.09.
The current year's Common Stock Shares Outstanding is expected to grow to about 21.6 M, whereas Net Loss is projected to grow to (56.4 M).

Protara Therapeutics Workforce Comparison

Protara Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 999. Protara Therapeutics holds roughly 28.0 in number of employees claiming about 2.8% of equities under Health Care industry.

Protara Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Protara Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
1.0
8
8
 850,500 
 57,468 
2024-06-01
0.4444
8
18
 80,000 
 388,332 
2024-03-01
1.0
10
10
 943,000 
 35,550 
2023-06-01
4.0
8
2
 80,000 
 9,310 
2023-03-01
1.5
9
6
 984,400 
 22,080 
2022-09-01
0.6667
6
9
 57,965 
 20,413 
2022-03-01
1.5
12
8
 632,131 
 44,928 
2021-06-01
12.0
12
1
 229,893 
 0.00 
2021-03-01
2.5
5
2
 373,750 
 9,722 
2020-09-01
0.175
7
40
 488,981 
 68,420 
2020-03-01
42.0
42
1
 4,736,098 
 0.00 
2019-12-01
1.0
3
3
 956,878 
 952.00 
2019-03-01
3.0
9
3
 904,666 
 22,000 
2018-06-01
13.0
13
1
 151,856 
 10,000 
2018-03-01
1.5
6
4
 1,230,000 
 18,742 
2017-12-01
1.2222
11
9
 196,229 
 154,491 
2017-09-01
0.6667
2
3
 26,666 
 10,000 
2017-06-01
3.0
15
5
 79,934 
 127,149 
2017-03-01
3.5
7
2
 401,551 
 70,221 
2016-12-01
1.0
3
3
 18,333 
 7,500 
2016-06-01
13.0
13
1
 116,070 
 58,742 
2016-03-01
0.5
1
2
 5,000 
 10,000 
2015-12-01
0.5455
6
11
 28,762 
 289,000 
2015-09-01
0.6667
2
3
 18,333 
 11,965 
2014-12-01
0.4312
47
109
 15,872,791 
 243,543,028 

Protara Therapeutics Notable Stakeholders

A Protara Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Protara Therapeutics often face trade-offs trying to please all of them. Protara Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Protara Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MBA MPHVP CoFounderProfile
William ConklingChief OfficerProfile
Jesse SheffermanPrincipal CoFounderProfile
Leonardo MDChief OfficerProfile
Jathin MDExecutive OfficerProfile
Justine OMalleySenior AffairsProfile
Kristine RosseVP OfficerProfile
Patrick MBAChief OfficerProfile
Mary JDGeneral SecretaryProfile
Hannah FryPrincipal ControllerProfile
Mary GrendellGeneral SecretaryProfile
Shane WilliamsChief OfficerProfile

About Protara Therapeutics Management Performance

The success or failure of an entity such as Protara Therapeutics often depends on how effective the management is. Protara Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Protara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Protara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.25)(0.26)
Return On Capital Employed(0.29)(0.30)
Return On Assets(0.25)(0.26)
Return On Equity(0.27)(0.28)
Please note, the presentation of Protara Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Protara Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Protara Therapeutics' management manipulating its earnings.

Protara Therapeutics Workforce Analysis

Traditionally, organizations such as Protara Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Protara Therapeutics within its industry.

Protara Therapeutics Manpower Efficiency

Return on Protara Therapeutics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.6M
Net Loss Per Executive3.7M
Working Capital Per Employee5.8M
Working Capital Per Executive13.4M

Complementary Tools for Protara Stock analysis

When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Commodity Directory
Find actively traded commodities issued by global exchanges
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios